Navigation Links
Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury
Date:11/17/2014

MENLO PARK, Calif., Nov. 17, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane S. Lebkowski, Ph.D., Asterias' President of Research and Development, will participate in a live Google Hangout session presented by the California Institute for Regenerative Medicine (CIRM) discussing the latest progress in stem cell-based therapies for spinal cord injury (SCI).

The CIRM Google Hangout session is scheduled for Tuesday, November 18, 2014, from 12:00 to 1:00pm PT (3:00 to 4:00pm ET). To access the event, please visit http://bit.ly/1sh1Dsm.

The session will include a discussion of Asterias' CIRM-funded Phase 1/2a dose escalation clinical trial for SCI. In addition to Dr. Lebkowski, participants include Roman Reed, a tireless advocate for stem cell research and SCI treatments, and Kevin Whittlesey, Ph.D., a CIRM science officer. Mr. Reed will provide the patient advocate community's perspectives, and Dr. Whittlesey will discuss other CIRM-funded research that aims to better understand SCI and to bring stem cell-based therapies to clinic trials.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias' two clinical development programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company's proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.  

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Asterias Biotherapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
2. Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
3. Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
4. Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
5. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
6. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
7. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
8. Northwest Biotherapeutics Announces Registered Direct Offering
9. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
10. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
11. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... ... The National Council on Strength and Fitness (NCSF), a ... Strength Coach credential has earned accreditation from the National Commission for Certifying Agencies ... qualified candidates for jobs in the Strength and Conditioning profession. The CSC distinction ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... a leading equipment provider in the modern ART laboratory, to provide hands-on training ... Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing vendor , ...
(Date:5/23/2017)... ... 23, 2017 , ... New patients looking for an alternative ... or without a referral, from the multi-specialty Dr. Smile practice. Dr. Esther Feldman ... in providing patients with the custom, convenient and long-lasting orthodontic treatment that helps ...
(Date:5/22/2017)... ... 22, 2017 , ... Dr. Kiya Green, a periodontist in ... surgery treatments, including crown lengthening and gum reduction surgery, with or ... functional procedures to help patients improve their oral health, reduce gummy smiles and ...
(Date:5/22/2017)... ... 22, 2017 , ... Faithfully following pop culture, people today are forever in ... shaped through fitness programs. It carries on to skin nourished, pampered and nurtured to ... radiant smile. CDA has found that just like a perfectly cut and ...
Breaking Medicine News(10 mins):